(AP) - A bipartisan investigation by U.S. senators finds that the makers of a breakthrough drug for hepatitis C infection put profits before patients in pricing the $1,000-per-pill cure.
The report released Tuesday by the Senate Finance Committee concludes that California-based Gilead Sciences was focused on maximizing revenue even as its own analysis showed a lower price would allow more patients to be treated for the liver-wasting disease.
Gilead's first breakthrough pill was called Sovaldi. The company now has a more expensive next-generation pill called Harvoni.
Sens. Ron Wyden, Democrat of Oregon, and Chuck Grassley, Republican of Iowa, said their 18-month investigation found that the high price tag significantly limited patient access and heaped huge costs on federal and state health care programs.
CapRadio provides a trusted source of news because of you. As a nonprofit organization, donations from people like you sustain the journalism that allows us to discover stories that are important to our audience. If you believe in what we do and support our mission, please donate today.